ABSTRACT
Resumen Esta revisión consiste en una puesta al día del tratamiento antiplaquetario y la interacción que presenta con los hipoglucemiantes orales en pacientes diabéticos con cardiopatía isquémica. Re sumimos los principales mecanismos fisiopatológicos que intervienen en el aumento del riesgo cardiovascular en este grupo, los efectos de la combinación entre los hipoglucemiantes orales, sus efectos antitrombóticos y su interacción con los antiplaquetarios y, por último, los trabajos que estudiaron los beneficios de los antiplaque tarios en pacientes diabéticos en diferentes escenarios de la cardiopatía isquémica. Los variados mecanismos de acción implican una mejora del control de la glucemia, del aumento de la biodisponibilidad del óxido nítrico, reducción del estrés oxidativo y, para ciertas moléculas, una inhibición directa de la activación y de la agregación plaquetaria.
Abstract This review is an update on antiplatelet therapy and its interaction with oral hypoglycemic agents in diabetic patients with ischemic heart disease. We summarize the main pathophysiological mechanisms that intervene in diabetic patients and that increase the ischemic risk, the effects of the combination of oral hypoglycemic agents, their antithrombotic ef fects and their interaction with antiplatelet, and finally the studies that demonstrated the benefits of antiplatelet in diabetic patients in different scenarios of ischemic heart disease. The different mechanisms of action involve improved glycemic control, increased bioavailability of nitric oxide, reduced oxidative stress and, for certain mol ecules, direct inhibition of platelet activation and aggregation.
ABSTRACT
Background:The prevalence of diabetes mellitus, is a major health concern that affects people around the world, and is increasing yearly. When blood glucose levels go below normal, a condition known as hypoglycemia, an immediate consequence of diabetes mellitus, occurs. The International Diabetes Federation reported thatthere were 451 million diabetics globally in 2017 and by 2045, it is anticipated that there will be 693 million. The objective of this study was to assess the level of knowledge of diabetic patient regarding hypoglycaemia and to find out the association between the levels of knowledge of diabetic patient on hypoglycaemia with their selected demographic variable.Methods:A descriptive cross-sectional study, was carried out in the month of June 2022. A semi-structured questionnaire was used to interview 100 study participants who were diabetes patients who had been admitted to the medical ward and who had visited the endocrinology outpatient department.Results:52% of the samples had fair knowledge on hypoglycemia, while 23% of them had poor knowledge. Demographic variable such as age, income, treatment, frequency of taking medicine, experience of symptoms of hypoglycemia and dietary habit were statistically significant with the level of knowledge, p<0.05.Conclusions:The study's findings highlighted the fact that most diabetes mellitus patients had a fair understanding of hypoglycemia. The health care personnel should also take time and efforts to educate patients about the sign of hypoglycemia. So that hypoglycemic episodes and morbidity could be reduced or prevented at primordial level.
ABSTRACT
ABSTRACT: Study Design: This mixed-methods study. Objective: To describe action plans related to the behavior of adher-ence to oral antidiabetic medications produced by people with type 2 diabetes mellitus and identify the challenges and coping strategies for the establishment of this behavior. Methods: The study followed-up 44 people with type 2 diabetes mellitus who used oral antidiabetic medications from southeast Brazil. Adults were invited to build action and coping plans based on the Implementation Intention Theory.The plans were quantitative and qualitatively ana-lyzed. Results: Action plans included three major themes: (1) binding oral antidiabetic medication to time markers or the sleep/wake cycle; (2) in specific environments; (3) associated with daily life activities. The motivation for coping with the perceived barriers focused on placing the pills in visible places, asking for help from family mem-bers, establishing a routine and feeding properly. Conclusions: The most effective way to manage satisfactory oral antidiabetic medication adherence seems to be recognizing the perceived barriers by patients. The implementation of specific and individualized action and coping plans to overcome perceived barriers was the stark difference. (AU)
RESUMO: Desenho do estudo: Estudo de método misto. Objetivo: Descrever planos de ação relacionados ao comportamento de adesão aos antidiabéticos orais elaborados por pessoas com diabetes mellitus tipo 2 e identificar as barreiras percebidas e respectivas estratégias de enfrentamento para efetivação desse comportamento. Métodos: O estudo envolveu 44 pessoas com diabetes mellitus tipo 2 que utilizavam antidiabéticos orais na região sudeste do Brasil. Adultos foram convidados a construir os planos de ação e de enfrentamento de obstáculos baseados sobre a Teoria da Ativação da Intenção. Os planos foram analisados quantitativa e qualitativamente. Resultados: Os planos de ação incluíram três temas principais: (1) Associar a tomada dos antidiabéticos orais aos marcadores de tempo ou ao ciclo de sono / vigília; (2) em ambientes específicos; (3) associados às atividades de vida diária. Os planos de enfrentamento das barreiras percebidas centraram-se em colocar os comprimidos em locais visíveis, pedir ajuda aos familiares para evitar esquecimento, estabelecer rotina e alimentar-se adequadamente. Conclusões: A forma mais eficaz de manejar a tomada de antidiabéticos orais de modo satisfatório parece ser o reconhecimento das barreiras percebidas pela própria pessoa. A implementação de ações específicas e individualizadas bem como de planos de enfrentamento para superar as barreiras percebidas foi o diferencial neste estudo. (AU)
Subject(s)
Humans , Male , Female , Adaptation, Psychological , Planning Techniques , Health Strategies , Diabetes Mellitus, Type 2 , Medication AdherenceABSTRACT
Post-transplant diabetes mellitus (PTDM) often occurs after solid organ transplantation, and treatment of PTDM is different from that of type 2 diabetes mellitus, the current research in this field is increasing gradually. The present paper summarizes the characteristics of blood glucose change in PTDM, risk assessment, the safety of hypoglycemic drugs, and the effect of immunosuppressive drugs on blood glucose in PTDM patients, and focuses on the efficacy and safety of new hypoglycemic drugs in PTDM patients, as well as the clinical research evidence such as the type of immunosuppressant used and the formula of administration has been summarized, so as to select a more optimized PTDM treatment options.
ABSTRACT
Objective To investigate the effects of Maiqi-Jiangtang pill on the glycolipid level in type 2 diabetic ob/ob mice.Methods The 8-week old male ob/ob mice were randomly divided into Maiqi-Jiangtang pill high- (8 g/kg), medium- (4 g/kg), low- (2 g/kg) dose groups. All the mice orally adiministered with the drugs once a day for 10 weeks. The same week age normal C57BL/6J control mice and ob/ob model group mice were orally administered with the equal volume solvent. The body weight per week were recorded. The fasting blood-glucose (FBG) was measured by glycemic instrument. The content of TG, TC, HDL-C, LDL-C in serum, and TG and TC content in liver were determined by biochemical method. The liver index was calculated.Results Compared with ob/ob model group, there was no significant change in body weight of mice administered with Maiqi-Jiangtang pill for 10 weeks. Compared with the model group, the low-, medium- dose Maiqi-Jiangtang pill could significantly decrease the FBG (7.43 ± 1.71 mmol/L,7.84 ± 1.09 mmol/L vs.8.95 ± 0.96mmol/L), the high- dose Maiqi-Jiangtang pill could significantly reduce the TG (0.93 ± 0.16 mmol/L vs.1.18 ± 0.26 mmol/L) and LDL-C (2.10 ± 0.51 mmol/L vs.2.56 ± 0.44 mmol/L) content in serum of ob/ob mice (P<0.05), increase the HDL-C/LDL-C ratio (2.40 ± 0.39vs.1.96 ± 0.24) in serum (P<0.01), decrease the liver weight (3.52 ± 0.26 gvs. 3.98 ± 0.35 g) and the liver index (0.063 ± 0.004vs. 0.071 ± 0.006) (P<0.05). Compared with the model group, the low dose Maiqi-Jiangtang pill could also significantly decrease the TG level (0.63 ± 0.25 mmol/gvs. 1.05 ± 0.67 mmol/g) in liver and significantly increase the HDL-C/LDL-C ratio (2.30 ± 0.44vs. 1.96 ± 0.24) in serum (P<0.05).Conclusions The Maiqi-Jiangtang pill can reduce lipid in serum and liver of ob/ob mice while it can decrease the blood glucose, which need to further study its mechanism.
ABSTRACT
Parkinson's disease is one of the most common neurodegenerative diseases,characterized by progressive degeneration of dopaminergic neurons.Diabetes is one of its common comorbidities,because both are affected by genetic factors and various environmental factors,as well as remarkably similar dysregulated pathways.The relationship between the two is receiving more and more attention.In particular,application of hypoglycemic drugs in Parkinson's disease has become a research hotspot in recent years.This article reviews the clinical features of Parkinson's disease and diabetes,the clinical features of Parkinson's disease with diabetes,and the application of hypoglycemic agents in Parkinson's disease.
ABSTRACT
Objective To evaluate and analyze the drug-drug interactions(DDI)of different antidiabetic drugs.Methods DDI database Lexi-InteractionTMwas used to evaluate DDI for 28 commonly used antidiabetic medications(including insulin and 27 non-insulin preparations).Results 882 DDIs were identified for 28 drugs.Category C was the top rated DDI(69.8%). Category C,D,X were accounted for 91.2% of the total DDI.28 medication combinations belonged to category X,which should be avoided to use together.Sulfonylureas had the most DDI,followed by metformin.Alpha-glucosidase inhibitors had least DDI.Conclusion Hypoglycemic drugs with less DDI,such as α-glycosidase inhibitors,glucagon-likepeptide1(GLP-1)an-alogs and sodium-dependent glucose transporters 2 inhibitor(SGLT2i)should be considered with high priority for patients tak-ing multiple antidiabetic medications,elderly patients and patients with liver-kidney dysfunction.
ABSTRACT
Objective:To explore the characteristics of prevailing factors and their influence on esophageal cancer in Xinjiang. Meth-ods:Patients diagnosed with esophageal cancer from January 2010 to January 2016 were selected from the Xinjiang Medical Universi-ty First Affiliated Hospital and categorized as the patient group. Patients without cancer admitted to the same period were classified as the control group. Case control study and correlation analysis between esophageal cancer and type 2 diabetes were performed. Re-sults:Type 2 diabetes (≥2 years), as a risk factor, is associated with esophageal cancer. The use of insulin (≥2 years) can increase the risk of esophageal cancer. Smoking, drinking, hyperlipidemia, body mass index≥24, and esophageal diverticulum esophageal cancer are also risk factors. Conclusion:The risk factors for esophageal cancer are prevalent among patients with type 2 diabetes patients. In-sulin use is also correlated with the occurrence of esophageal cancer. Further studies must be performed to develop secondary preven-tion for diabetic patients susceptible to esophageal cancer in high-risk subgroups.
ABSTRACT
Objective To study the rationality of hypoglycemic drugs in patients with gastroparesis. Methods The mechanism of gastroparesis was analyzed, and the mechanism, indications, adverse reactions and contraindications of common hypoglycemic agents were studied. Results There were significant differences in the mechanism of gastric hypoglycemia and hypoglycemic therapy. The mechanism of action and the application of the patients were obvious. According to the characteristics of the patients, the selection of the appropriate drugs could improve the clinical curative effect and ensure the safety of the drug. Conclusion The pathogenesis of gastroparesis is more complicated. The clinical practice should be based on the pathogenesis of the patients and the hypoglycemic drug regimen.
ABSTRACT
Objective To observe the expression of NGF mRNA in rats brain with diabetes and the effects of hypoglycemia caused by oral antidiabetic drugs on NGF mRNA.Methods A total of 64 adult Wistar rats were randomly divided into control group(16)and diabetes model group(48).Using high fat and high sugar diet+intraperitoneal injection of streptozotocin to prepare type 2 diabetes model.The diabetes model group was randomly divided into non-medication group(16),oral medication group (16) and hypoglycemia group(16).The oral medication rats and hypoglycemia rats were given glibenclamide+metformin by intragastric administration once daily for 12 d,the dose of hypoglycemia rats was 5 times of treatment rats.The brain tissues of rats in each group were used respectively the RT-PCR method to detect NGF mRNA at 3,6,9 and 12 d.Results Compared with the control group,the expression of NGF mRNA in the brain tissues of the 3 groups of diabetic rats were decreased in different degrees and the non-medication group was the most obvious(P＜0.01).Compared with the non-medication group,the oral medication group was significantly increased(P＜0.01),the hypoglycemia group was further decreased(P＜ 0.01).Conclusion Oral hypoglycemic drugs can effectively enhance the expression of NGF mRNA in brain tissue of diabetic rats,but hypoglycemia caused by Oral antidiabetic drugs can make the expression of NGF mRNA further decreased.So hypoglycemia is not conducive to the repair of diabetic neuropathy.
ABSTRACT
Objective:To develop the intelligent management system for diabetes medication knowledge base with the help of community hospital information platform.Methods:Based on the China Type 2 Diabetes Prevention Guide (2013 edition),National Essential Drugs (2012 edition) and the relevant package inserts,the knowledge base of diabetes medication was established.Results:The information platform could make interception beforehand,warning in the process of medication and provide attentions for physicians after treatment to determine rational medication.Conclusion:The intelligent management system for diabetes medication knowledge base can promote physicians to firmly grasp the principles of drug treatment,simplify treatment regimen,select effective drugs with reasonable prices and provide individualized treatment.
ABSTRACT
Objective:To evaluate the utilization of oral hypoglycemic drugs in 34 hospitals of Nanjing to provide clinical reference for the drug rational use. Methods: According to the sales data of oral hypoglycemic drugs in 34 hospitals of Nanjing from 2011 to 2013,the utilization of oral hypoglycemic drugs was analyzed retrospectively in respect of consumption sum,DDDs and defined daily cost ( DDC) by daily dose limit analysis method. Results: The top 3 oral hypoglycemic drugs in the list of consumption sum were acarbose,glimepiride and metformin. In terms of DDDs,glimepiride, metformin and gliclazide ranked the top 3. The consumption sum and DDDs of oral hypoglycemic drugs were increased year by year in Nanjing. The ratio of serial number of consumption sum and DDDs was from 0. 3 to 2. 0. Conclusion: The demanded quantity of oral hypoglycemic drugs is increased year by year from 2011 to 2013. The application conforms to the safe, effective and economic principle. The drugs should be chosen according to the drug characteristics in order to improve the abnormal glucose metabolism and prevent and treat the complications.
ABSTRACT
Metabonomics is an emerging platform for technology.It provides a new method in study of drugs.This article summarized evidences derived from recent metabonomics studies regarding hypoglycemic drugs.We collected all proofs of body metabolite profiling in assessing drugs and exploring their potential mechanisms.An outlook of metabonomics for future research into hypoglycemic drugs was also postulated.
ABSTRACT
Background: Diabetes mellitus refers to a group of common metabolic disorders that share the phenotype of hyperglycemia resulting from defects of reduced insulin secretion, decreased glucose utilization and increase in glucose production. It is estimated that there are currently 285 million people worldwide and this number is set to increase to 438 million by the year 2030. India has the highest number of patients with known diabetes worldwide, with a prevalence of 11.6%. The aim of the study was to evaluate the anti diabetic activity of ethanolic extract of leaves of plant Ocimum sanctum in alloxan induced diabetes in rats. Methods: The study was conducted on 4 groups of 6 rats each to evaluate the hypoglycaemic effect of ethanolic extract of Ocimum sanctum. Glibenclamide was used as a standard drug and the results were compared in reference to it. Tween 80 was given for both normal and diabetic control groups. The fasting blood sugar levels were recorded on 1st, 3rd, 5th, 7th, 10th days by glucometer. Results: The results indicate that the test compound ethanolic extract of Ocimum sanctum has significant and sustained oral hypoglycaemic activity, comparable with the hypoglycaemic effect of glibenclamide, a sulfonylurea. Conclusion: The hypoglycaemic potential of the test compound is found to be comparable with that of the standard drug glibenclamide.
ABSTRACT
Objective: To compare the safety and efficacy of the long-acting analog insulin glargine and human premix insulin in patients with type 2 diabetes who were previously treated with oral hypoglycemic drugs alone but inadequately controlled. Research design and methods: A total of 750 subjects with type 2 diabetes who were receiving oral hypoglycemic drugs for diabetes control were randomized to receive insulin glargine once-daily (n = 370) or human premix insulin twice-daily (n = 380) for 24 weeks in an open-label, tertiary center study. Doses were adjusted systematically to obtain target fasting glucose <100 mg/dl. Outcomes included fasting blood sugar, glycosyloted hemoglobin (HbA1C) levels, change in weight and insulin dose from study start to end. Results: At the start of study, age range was 30-70 years, BMI was 26.48 ± 6.3 kg/m2 and HbA1C was 11.9 ± 3.1% (mean ± SD) for both groups. The mean change (means ± SD) in HbA1C from baseline to endpoint was similar in the insulin glargine group (−3.0 ± 1.68%) and the human premix insulin group (−2.89 ± 1.79%) (p = 0.3861). The symptomatic hypoglycemic episodes were greater with human premix insulin than with glargine (significance level 0.00002). Subjects in the insulin glargine group experienced less weight gain than those in the premix human insulin group (0.4 vs 1.4 kg, p < 0.0001). Conclusions: In patients with type 2 diabetes, once-daily bedtime insulin glargine is as effective as twice-daily human premix insulin in improving and maintaining glycemia control. In addition, insulin glargine demonstrates a lower risk of symptomatic hypoglycemia and less weight gain compared with human premix insulin. The treatments were associated with similar reductions in fasting glucose levels and HbA1C levels.
ABSTRACT
BACKGROUND:Diabetes mel itus is a common complication after kidney transplantation. OBJECTIVE:To investigate the risk factors for diabetes mel itus after kidney transplantation diabetes mel itus risk factors and clinical treatment based on integrative medicine. METHODS:Literatures concerning diabetes mel itus after kidney transplantation were retrieved in the database, and the articles that met the study criteria were analyzed. In this paper, we analyzed the risk factors for diabetes mel itus and concluded the therapies for diabetes mel itus after kidney transplantation. RESULTS AND CONCLUSION:Diabetes mel itus after kidney transplantation is an abnormal glucose metabolism caused by multiple factors, which is related to age, body mass index, lipid levels, immunosuppressant program, frequency of acute rejections, and cumulative dose of glucocorticoid. Periodic monitoring of blood glucose after kidney transplantation contributes to the earlier detection of the occurrence of diabetes mel itus. Integrative medicines that can lower blood glucose level and immunosuppressant adjustment can be effective for the treatment of diabetes mel itus after kidney transplantation.
ABSTRACT
Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.
ABSTRACT
OBJECTIVE:To evaluate the status quo and trend of the consumption of hypoglycemic drugs in our hospital.METHODS:The data regarding the consumption sum and the market share of each drug manufacturer of the hypoglycemic drugs between 2006 and 2008 were collected and the use of the hypoglycemic drugs in the clinic was analyzed statistically.RESULTS:The consumption sum of hypoglycemic drugs increased year by year,up 19.75% in 2007 vs.39.93% in 2008,and up 120.53% for the drugs promoting insulin secretion vs.72.73% for biological products in 2008.CONCLUSION:There is a great potential for the development of hypoglycemic drugs,and the consumption sum and sales amount of which are expected to experience a fast increase.
ABSTRACT
OBJECTIVE:To investigate the effects of different kinds of hypoglycemic drugs on the QT interval dispersion in patients with type 2 diabetes mellitus. METHODS: The differences of QT interval dispersion (QTd) and corrected QT interval dispersion (QTcd) in 318 patients with type 2 diabetes (of which, 129 were assigned to receive insulin, 110 glibenclamide and 79 metformin) and 33 healthy volunteers (normal control) were compared. RESULTS: The QTd and QTcd were all significantly higher in glibenclamide group than in the other three groups(P0.05). CONCLUSION: The results suggest that glibenclamide and insulin may increase the QTd and QTcd in patients with type 2 diabetes.
ABSTRACT
OBJECTIVE: To evaluate the use of oral hypoglycemic drugs in our hospital in order to provide an reference for rational use of drugs in clinic. METHODS: DDDs, sales volume, and daily expenses of drugs in our hospital from 2001to 2003 were analyzed with the method of DDD analysis. RESULTS: The varieties, quantities and sales volumes of oral hypoglycemic drugs increased year by year. The top 3 hypoglycemic drugs in respect of DDDs were dimethylbigmide, gliclazide, and glipizide. The top 3 hypoglycemic drugs in respect of sales volume were glipizide, acarbose, and dimethylbimide. The ratio of sales volume sequencing to that of DDDs was between 0.2～4. CONCLUSIONS: Gliclazide and dimethylbimide are most widely used and their prices are reasonable; Acarbose is expensive, and its sales volume has not grown in pace with DDDs.